Literature DB >> 14650154

[Change of T lymphocyte and its activated subsets in SARS patients].

Xue-ying Yu1, Yuan-chun Zhang, Cheng-wu Han, Ping Wang, Xiang-jun Xue, Yu-long Cong.   

Abstract

OBJECTIVE: To study abnormal changes of T lymphocyte and its activated subsets in severe acute respiratory syndrome (SARS) patients.
METHODS: Flow cytometer with multi-color flouroscence and hematology analyzer were used to detect the expression of T lymphocyte and its activated a subsets in 240 SARS patients including 50 cases of critical type and 190 cases of common type.
RESULTS: Statistical analysis by means of SAS software showed that there was significant decrease in absolute counts (AC) of T lymphocyte and its subsets in SARS patients when compared with normal people, while percentages (PC) of CD3+CD25+ and CD3+ HLA-DR+ subsets were increased markedly. Compared with common type, there was significant decrease in absolute counts of critical type of T lymphocyte, CD4+, CD25+CD3+, CD28+CD4+, and CD95+CD4+subsets. The ACs of T lymphocytes including CD4 and CD8 subsets in different phases were as below: III > II > I. The ACs of subsets involved in activation such as CD3+ HLA-DR+/lym, CD3+CD25+/lym, CD28+CD4+/CD4, CD28+CD8+/CD8, and CD38+CD4+/CD4 all were highest in group III. In addition, the AC and PC of CD95+CD4+/CD4 and CD95+CD8/CD8 subset in group III were highest while group I was lowest.
CONCLUSIONS: With depressing cellular immunity, the activation of T lymphocytes were suppressed obviously in SARS patients, especially for critical patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14650154

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  8 in total

Review 1.  T cell-mediated immune response to respiratory coronaviruses.

Authors:  Rudragouda Channappanavar; Jincun Zhao; Stanley Perlman
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 2.  Lessons for COVID-19 Immunity from Other Coronavirus Infections.

Authors:  Alan Sariol; Stanley Perlman
Journal:  Immunity       Date:  2020-07-14       Impact factor: 31.745

Review 3.  SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development.

Authors:  Guilherme Antonio de Souza Silva; Suéllen Pedrosa da Silva; Marcos Aurélio Santos da Costa; Abdênego Rodrigues da Silva; Robson Raion de Vasconcelos Alves; Fernanda das Chagas Ângelo Mendes Tenório; Alanne Rayssa da Silva Melo; Antonio Carlos de Freitas; Cristiane Moutinho Lagos de Melo
Journal:  J Gynecol Obstet Hum Reprod       Date:  2020-06-26

4.  Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review).

Authors:  Jin Shang; Lingyao Du; Ning Han; Duoduo Lv; Jiayi Wang; Hailing Yang; Lang Bai; Hong Tang
Journal:  Mol Med Rep       Date:  2021-02-12       Impact factor: 2.952

5.  Immunomodulatory and anti-SARS activities of Houttuynia cordata.

Authors:  Kit-Man Lau; Kin-Ming Lee; Chi-Man Koon; Crystal Sao-Fong Cheung; Ching-Po Lau; Hei-Ming Ho; Mavis Yuk-Ha Lee; Shannon Wing-Ngor Au; Christopher Hon-Ki Cheng; Clara Bik-San Lau; Stephen Kwok-Wing Tsui; David Chi-Cheong Wan; Mary Miu-Yee Waye; Kam-Bo Wong; Chun-Kwok Wong; Christopher Wai-Kei Lam; Ping-Chung Leung; Kwok-Pui Fung
Journal:  J Ethnopharmacol       Date:  2008-03-30       Impact factor: 4.360

6.  Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.

Authors:  Min-Sheng Zhu; Ying Pan; Hua-Qun Chen; Yue Shen; Xiao-Chun Wang; Yong-Jun Sun; Kai-Hua Tao
Journal:  Immunol Lett       Date:  2004-04-15       Impact factor: 3.685

7.  Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.

Authors:  Yafei Wang; Ying Zhou; Zhen Yang; Dongping Xia; Yi Hu; Shuang Geng
Journal:  Respiration       Date:  2020-08-25       Impact factor: 3.580

Review 8.  The Immune Response and Immunopathology of COVID-19.

Authors:  Esmaeil Mortaz; Payam Tabarsi; Mohammad Varahram; Gert Folkerts; Ian M Adcock
Journal:  Front Immunol       Date:  2020-08-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.